Antibodies for COVID-19

New in vivo study data!

Twist recently conducted pre-clinical studies aimed at understanding the protective nature of our antibody leads in vivo against COVID-19. The data show that TB202-3 and TB202-63, both single-domain VHH “nanobodies” protect against weight loss at the lowest dose of 1 mg/kg in preclinical hamster challenge models. In addition, TB181-36, an IgG antibody discovered through Twist’s collaboration with Vanderbilt University Medical Center (VUMC), was found to protect against weight loss at 5 mg/kg and 10 mg/kg.

SEE THE DATA

Twist Biopharma COVID Antibodies Program

Twist Biopharma has developed a set of antibodies that targets the SARS-CoV-2 Spike Protein with high binding affinity and specificity.  Several antibodies also show the ability to block S1 binding to ACE2.

We have also developed a set of antibodies targeting the extracellular domain of the ACE2 receptor. These antibodies have high binding affinity and have been demonstrated to inhibit the binding of the S1 protein to ACE2 in vitro.  

All antibodies are fully human and are either hIgG1, IgG2, or IgG1 VHH Fc making them ideal as potential candidates for both diagnostic and therapeutic uses.
 

Twist Human Anti-ACE2 Antibodies

The human anti-ACE2 receptor antibodies exhibit high affinity to the ACE2 receptor indicating that they have the potential to be developed as blocking or competitive antibodies for therapeutic applications.

For more information on Twist’s antibody capabilities

Biopharma Resource Library